Detail akcie ABVC BioPharma Rg online

Business Summary: ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
Financial Summary: BRIEF: For the three months ended 31 March 2025, ABVC Biopharma Inc revenues decreased from $1K to $0K. Net loss decreased 70% to $842K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Stock-based compensation decrease of 98% to $49K (expense), Selling, general and administrative expe decrease of 22% to $498K (expense).